🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We would like to extend a warm welcome to our new Members Agility Life Sciences, GOM Therapeutics, paragreenassociates.com, PharmEnable Therapeutics, Science Entrepreneur Club, scarlet-tx.com, axxam.com, Seroxo - Impatient Diagnostics and Carter Jonas

We are delighted to welcome Dr Kyla Grimshaw into the team as our Director of Biology. Kyla brings 20+ years' experience in the #biotech industry, specialising in #cancerbiology. Her wealth of experience will be invaluable in developing life-changing small molecule drugs 💊

Each fortnight we will be highlighting one of the #21toWatch Top21.2023. Dr Hannah Sore is the founder and CEO of PharmEnable Therapeutics, a company combining AI and medicinal chemistry expertise to develop the next generation of complex and 3D small molecule drugs cofinitive.com/21towatch/

PharmEnable is delighted to announce that we are expanding our drug discovery collaboration with covujese to work on a second neurological disease target. Read the full press release here: pharmenable.com/news/pharmenab… #drugdiscovery #medicinalchemistry #SBDD #PR

Our CBO, Dr Jelena Aleksic, is delighted to attend BioIndustry Association (BIA)'s TechBio UK 2023 today alongside other companies that are transforming #drugdiscovery through cutting edge #datadriven tech.

Our Senior Scientist, Dr Avene Colgan, and Alliance Manager, Dr Jessica Iegre, are attending @ELRIG_UK's #DrugDiscovery2023 conference this week. This year's conference covers themes from ‘omics to personalised #medicine, all focused on bringing new therapies from lab to patient

Our CBO Dr Jelena Aleksic is looking forward to meeting likeminded companies and potential partners at #BIOEurope this week. Reach out via the partnering platform to find out how we are re-imagining small molecule therapeutics - we would be delighted to meet with you.

We are delighted to welcome Dr Ignacio Viciano into the team. As a Senior Scientist, he is responsible for designing novel molecules within our drug discovery projects. He has extensive experience in #molecularmodelling and in silico #drugdiscovery across industry and academia.

Today our Director of Drug Discovery, Dr James Dale, is attending the 12th Annual Tumour Models Summit in London. This year's summit is focused on tools that increase clinical translatability and ensure safe, effective treatments for patients. #DrugDiscovery

At PharmEnable we are an interdisciplinary team working closely together to reimagine small molecule therapeutics using #AI. Last week, the whole team met up in Cambridge for a workshop focused on high performing teams and delivering maximum impact with our work.

We are looking forward to attending #Biotech Showcase in January. Interested in finding out how we are reimagining small molecule therapeutics through #AI? Reach out via the partnering platform, we would be delighted to meet with you.

Just a few days until #BiotechShowcase! Our CEO Dr Hannah Sore and CBO Dr Jelena Aleksic will be attending. Get in touch to find out how we are reimagining #SmallMoleculeTherapeutics through #AI. informaconnect.com/biotech-showca…

Our CEO Dr Hannah Sore is delighted to present today at the R42 x Perkins Coie's event: Breakthrough Ideas in Life Sciences, AI and Longevity. Hannah is sharing how we use AI to bring the specificity of biologics to small molecule drug design. Join us: lu.ma/jwnikezf

Enterprise Tuesday: Anticipating the future of AI in health, pharma and more 👇 13th Feb, 6.30pm. Join Cambridge Judge as they host Hannah Sore (PharmEnable Therapeutics), Vincenzo Garzya (AstraZeneca) & Roeland Decorte (Decorte Future Industries) for this panel discussion. ow.ly/H0G550Qs0MK

We have an amazing line up of speakers for #EnterpriseTuesday on 13 Feb 2024. Looking forward to a great debate on the future of #AI in #health, #pharma and more. Register soon at jbs.cam.ac.uk/entrepreneursh… AstraZeneca PharmEnable Therapeutics Decorte Future Industries PrecisionLife Cambridge University

Our CEO Dr Hannah Sore is looking forward to presenting at o2h Group's first chaitime portfolio pitch day. To find out how we are pushing the boundaries of what is possible with small molecule therapeutics, follow this link and join us this afternoon: us02web.zoom.us/webinar/regist…

We are delighted to welcome Joseph Yap to the #team. Joseph is an organic chemist by training with extensive experience in software development. As part of our scientific team, Joseph's work will be contributing to our mission to reimagine small molecule therapeutics through #AI

Join us tomorrow at Enterprise Tuesday in Cambridge, where our CEO Dr Hannah Sore will be discussing how far #AI can go to revolutionise the #healthcare sector. jbs.cam.ac.uk/entrepreneursh…

Our CBO Dr Jelena Aleksic is looking forward to attending BIO-Europe Spring next month. Reach out via the partnering platform to find out how we are reimagining small molecule therapeutics through AI. We hope to see you there! informaconnect.com/bioeurope-spri… #BIOEuropeSpring

We are delighted to welcome Dr Ian Collins to our board! Together, we’ll push the boundaries of what #SmallMolecules can achieve for #Oncology and #CNSdisease patients. Find out about Ian’s expertise: pharmenabletx.com/news/clinical-… #DrugDiscovery #BoardMember #pharma